Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00042302
Status:
TERMINATED
Last Update Posted:
2012-05-23
First Post:
2002-07-26
Brief Title:
A Double-Blind Randomized Placebo-Controlled Multicenter Phase III Study of Tariquidar PaclitaxelCarboplatin as First-Line Therapy in Non-Small Cell Lung Cancer NSCLC
Sponsor:
Organization:
QLT Inc
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
540
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: